Connect Biopharma Holdings Ltd
CNTB Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.84
KIRA · Stoqly’s AI analyst, in plain words
- Connect Biopharma Holdings Ltd had $0.1M of revenue in fiscal 2025, down 99.8% on the year before.
- Its operating margin was −90,740.6%, down 90,654.4 pts: of every 100 in sales, about −90,741 is left after running the business.
- Connect Biopharma Holdings Ltd lost $55.5M in fiscal 2025.
- Free cash flow was −$51.6M in fiscal 2025, −80,687.5% of revenue.
Market cap
$53.0M
P/E
—
Revenue
$0.1M
Net income
−$55.5M
Free cash flow
−$51.6M
Operating margin
−90,740.6%
Connect Biopharma Holdings Ltd in 30 seconds · fiscal 2025
Are sales growing?
−99.8%
No. Sales fell 99.8% last year.
Does it make a profit?
−86,687.5%
No. It lost money last year.
Does profit turn into cash?
−80,687.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Connect Biopharma Holdings Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- Connect Biopharma Holdings Ltd
- CIK
- 0001835268
Connect Biopharma Holdings Ltd · CNTB
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.0M | $26.0M | $0.1M |
| Revenue growth | — | — | −99.8% |
| Operating margin | — | −86.2% | −90,740.6% |
| Net income | −$62.1M | −$15.6M | −$55.5M |
| Net margin | — | −60.0% | −86,687.5% |
| Diluted EPS | −$1.13 | −$0.28 | −$1.00 |
| Cash | |||
| Cash from operations | −$47.7M | −$23.6M | −$51.2M |
| Capital expenditure | $0.1M | $0.8M | $0.4M |
| Free cash flow | −$47.8M | −$24.4M | −$51.6M |
| FCF margin | — | −93.6% | −80,687.5% |
| Share count change | — | 0.3% | 0.8% |
| Debt and strength | |||
| Cash and short-term investments | $118M | $93.7M | $44.3M |
| Shareholders' equity | $101M | $92.2M | $42.0M |
| Current ratio | 4.8x | 11.5x | 3.7x |
| Returns and quality | |||
| Return on equity | −61.2% | −16.1% | −82.7% |
| Return on tangible equity | −61.2% | −17.0% | −132.3% |
| Piotroski F-score | — | 3 | 1 |
| Altman Z'' | −3.0 | 3.7 | −22.8 |
Insiders bought, 12 months
$4.4M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Connect Biopharma Holdings Ltd · CNTB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.84 a share, the company is worth $53.0M.
Source: SEC EDGAR XBRL filings (CIK 0001835268). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.